Jason Najum's Blog

The psychedelic medicine sector provides some unique value investment opportunities. Here’s why Cybin could be the best value bet among this group of biotech pioneers.

The FDA has rejected MDMA therapy, but this setback could potentially benefit other psychedelic stocks.

A look at the FDA's upcoming decision on MDMA therapy and how it might affect other psychedelic stocks.

As we close out the year, let’s take a look back at some of the more important milestones in the psychedelic medicine space. From legalization to clinical trials, the psychedelic sector continued to make steady progress on all fronts.

The psychedelic medicine industry continues to get attention and gain credibility in the investment world.

Microdose's editor Jason Najum shares his personal experience with ketamine psychedelic therapy.

Microdose digs in and gives you a deeper look at Atai's programs and developmental portfolio

Psychedelic startups face a more challenging time raising capital amid market volatility.

The ability to raise capital is one of the most important factors in the success of any company, and is downright essential for biotech startups faced with the lean years of long R&D horizons.

MindMed announced that the Nasdaq listing is official and will begin trading next week. MindMed shareholders and the psychedelic industry as a whole have been waiting for this moment.